Cerebramed Company

CerebraMed develops a technology for drug therapy designed to treat patients by correcting malfunctioning cellular processes. CerebraMed has developed proprietary GSK-3 inhibitors as drug candidates. The company's findings are relevant for the treatment of both Alzheimer's and amyotrophic lateral sclerosis.
Technology: N/A
Industry: Personalized Medicine
Headquarters: Tel Aviv, Israel
Founded Date: Undisclosed
Employees Number: Undisclosed
Funding Status: N/A

Register and Claim Ownership